Search
Close this search box.
Search
[custom_company_search_form]
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)

Stock Piper AI Index

Subscribe
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)
Hang Seng
17,444.30
(0%)
Dow Jones
40,345.41
(-1.01%)
Nikkei 225
36,391.47
(-0.72%)
FTSE 100
8,181.47
(-0.73%)
USD/AUD
0.6611
(-0.36%)
Bitcoin
57,763.00
(-0.78%)
Oil
68.16
(-1.43%)
Gold
2,526.80
(-0.64%)
Lithium
36.58
(-3.5%)
Iron Ore
92.2
(1.3%)

Recce Pharmaceuticals Ltd

RCE

ASX

Recce Pharmaceuticals Ltd (RCE)is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives are RECCE 327, RECCE 435 and RECCE 529.

Latest Posts

Line Chart with Gradient
Price
$0.55
0.035 (6.86%)
At Close 06/09 (AEST)
Related Companies
AUSCANN GROUP HOLDINGS LTD
$AC8
TRAJAN GROUP HOLDINGS LIMITED
$TRJ
ANATARA LIFESCIENCES LTD
$ANR
DIMERIX LIMITED
$DXB
ACTINOGEN MEDICAL LIMITED
$ACWNB

Latest Posts

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) progresses clinical trials and secures additional funding

Positive data from clinical trials and new funding secured for anti-infective development

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) reports positive data from phase I/II UTI/urosepsis rapid infusion clinical trial

Phase I/II trial demonstrates efficacy of RECCE® 327 at highest tested dose of 4,000mg

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) receives ethics approval to centralise and broaden RECCE® 327 gel clinical trials

Phase II clinical trial to assess R327 gel for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) receives further R&D tax incentive rebate

Australian government supports Recce Pharmaceuticals with AUD $2,624,860.47 cash refund for R&D activities

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) secures WHO recognition for RECCE® 327

Added to WHO's list of Antibacterial Products in Clinical Development

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) doses first participants in uti/urosepsis trial

Company successfully doses participants at 4,000mg intravenously in phase I/II trial

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) approves high dose of 4,000mg for urinary tract infection/urosepsis trial

Independent Safety Committee clears R327 increase to 4,000mg intravenously over 30 minutes

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) progresses clinical trials and secures USD $2.2M grant for R327G

Phase I/II trials show promising results in UTI/Urosepsis and DFI, while R327G receives USD $2.2M grant for Burn Wound Infections

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) granted patent for RECCE® anti-infectives in Israel

State of Israel Patent Office grants new Patent Family 4 for RECCE's anti-infectives

RCE

$RCE

Recce Pharmaceuticals (ASX: $RCE) completes dosing for UTI/Urosepsis clinical trial

Phase I/II trial of RECCE® 327 at fast infusion rates paves way for Phase II efficacy trial

Load More
No More Posts
Related Companies
LITTLE GREEN PHARMA LTD
$LGP
HEXIMA LIMITED.
$HXL
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
$NSB
CLEO DIAGNOSTICS LTD
$COV
WELLFULLY LIMITED
$WFL

ASX News, First
& Fast.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

By clicking Subscribe, you agree to our Terms & Conditions

© 2024 Stock Piper. All rights reserved

© 2024 Stock Piper.
All rights reserved

Blog

Healthcare
Materials
Real Estate
Consumer Staples
Consumer Discretionary Brief
Utilities

Company

About us
Terms of use
Privacy Policy

Support

Request Form
Contact Support
FAQ
Glossary

Socials

Facebook
Twitter
LinkedIn
© 2024 Stock Piper. All rights reserved
Social Media Auto Publish Powered By : XYZScripts.com
Join FREE Newsletter

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions